

RELEVANT EVENT

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley del Mercado de Valores*), Grifols, S.A. ("Grifols") hereby informs that it has received the approval of the United States' Food and Drug Administration ("FDA") for its new state-of-the-art purification facility of Grifols Biologicals Inc. in Los Angeles, California, United States for the production of "Immune Globulin Injection" 10% for human use (Gamunex).

Grifols' products are used to treat rare and chronic diseases such as neurological disorder, immune deficiencies, hemophilia and genetic emphysema. The new purification plant will be operational in 2015 as planned.

With this approval by the FDA, Grifols increases its manufacturing capacity for Gamunex by a maximum amount of 17 million grams per year in this plant.

53 million euros have been invested in the new plant and over 100 new jobs will be created.

Barcelona, on 31 December 2014

Raimon Grifols Roura
Secretary to the Board of Directors